Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Biosensors
      • Chromatography
      • Flow Cytometry
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register
LC–MS strategies for advanced modalities: ADC, AOC, multidomain and RNA therapeutics 20 days 2 hours 30 mins 8 secs REGISTER NOW

Spotlight survey on antibody-drug conjugates

14 Apr 2015
General interest

As part of our Spotlight on antibody-drug conjugates (ADCs), Bioanalysis Zone carried out a survey to investigate the techniques used to study ADCs, the issues surrounding their analysis, as well as what the future may hold.

The results can be seen via our infographic. We will also be analyzing the results of the survey during our Spotlight panel discussion, which you can register for here.

 

Top content

  • Portable test detects four STIs in under an hour
  • Part two: Applications of PCR-based methods in gene therapy development
  • Mpox immune test validated during Rwanda outbreak response

Related tags

ADCs
Previous article Next article

Related articles

23 JAN 2019 INTERVIEWS
An author’s perspective: Wenying Jian on bioanalytical workflow for novel scaffold protein–drug conjugates
24 JUL 2019 ANTIBODIES | ADCS
LC–HRMS quantitation of intact antibody drug conjugate trastuzumab emtansine from rat plasma
31 MAR 2015 GENERAL INTEREST
Antibody–drug conjugates
14 AUG 2019 GENERAL INTEREST
Bioanalytical strategies for PK analysis of antibody–drug conjugate therapeutics using LC–HRMS & LC–MS/MS
14 DEC 2021 LBA
Poster: polyclonal solution for next generation multispecific antibody therapeutics
18 MAR 2013 GENERAL INTEREST
AMS provides a universal method for quantitation of biologics, ADCs and large molecules in preclinical development
  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Bioanalysis Zone